PURPOSE: We sought to evaluate the safety and the diagnostic success rate of percutaneous biopsies performed under intra-procedural (18)F-deoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) guidance for lesions difficult to see with conventional cross-sectional imaging. METHODS: From 2011 to 2013, consecutive clinically indicated percutaneous PET/CT-guided biopsies of 106 masses (mean size, 3.3 cm; range, 0.7-15.9 cm; SD, 2.9 cm) in bones (n = 33), liver (n = 26), soft tissues (n = 18), lung (n = 15) and abdomen (n = 14) were reviewed. The biopsy procedures were performed following injection of a mean of 255 MBq (SD, 74) FDG. Mean maximal standardized uptake value (SUV) of lesions was 8.8 (SD, 6.3). A systematic review of the histopathological results and outcomes was performed. RESULTS: Biopsies were positive for malignancy in 76 cases (71.7%, 76/106) and for benign tissue in 30 cases (28.3%, 30/106). Immediate results were considered adequate for 100 PET/CT biopsies (94.3%, 100/106) requiring no further exploration, and for the six others (5.7%, 6/106) benign diagnoses were confirmed after surgery (n = 4) or follow-up (n = 2). The consequent overall sensitivity and the diagnostic success of biopsy were therefore 100%. No significant differences in terms of detection of malignancy were observed between the different locations. Lesions > 2 cm or with SUV > 4 were not significantly more likely to be malignant. Complications occurred after four biopsies (3.7%, 4/106). CONCLUSION: Intra-procedural PET/CT guidance appears as a safe and effective method and allows high diagnostic success of percutaneous biopsies for metabolically active lesions.
PURPOSE: We sought to evaluate the safety and the diagnostic success rate of percutaneous biopsies performed under intra-procedural (18)F-deoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) guidance for lesions difficult to see with conventional cross-sectional imaging. METHODS: From 2011 to 2013, consecutive clinically indicated percutaneous PET/CT-guided biopsies of 106 masses (mean size, 3.3 cm; range, 0.7-15.9 cm; SD, 2.9 cm) in bones (n = 33), liver (n = 26), soft tissues (n = 18), lung (n = 15) and abdomen (n = 14) were reviewed. The biopsy procedures were performed following injection of a mean of 255 MBq (SD, 74) FDG. Mean maximal standardized uptake value (SUV) of lesions was 8.8 (SD, 6.3). A systematic review of the histopathological results and outcomes was performed. RESULTS: Biopsies were positive for malignancy in 76 cases (71.7%, 76/106) and for benign tissue in 30 cases (28.3%, 30/106). Immediate results were considered adequate for 100 PET/CT biopsies (94.3%, 100/106) requiring no further exploration, and for the six others (5.7%, 6/106) benign diagnoses were confirmed after surgery (n = 4) or follow-up (n = 2). The consequent overall sensitivity and the diagnostic success of biopsy were therefore 100%. No significant differences in terms of detection of malignancy were observed between the different locations. Lesions > 2 cm or with SUV > 4 were not significantly more likely to be malignant. Complications occurred after four biopsies (3.7%, 4/106). CONCLUSION: Intra-procedural PET/CT guidance appears as a safe and effective method and allows high diagnostic success of percutaneous biopsies for metabolically active lesions.
Authors: Eric Lis; Mark H Bilsky; Leszek Pisinski; Patrick Boland; John H Healey; Bernie O'malley; George Krol Journal: AJNR Am J Neuroradiol Date: 2004-10 Impact factor: 3.825
Authors: Lorenzo Monfardini; Lorenzo Preda; Gaetano Aurilio; Stefania Rizzo; Vincenzo Bagnardi; Giuseppe Renne; Sara Maccagnoni; Paolo Della Vigna; Disalvatore Davide; Massimo Bellomi Journal: Radiol Med Date: 2014-04-04 Impact factor: 3.469
Authors: Servet Tatli; Victor H Gerbaudo; Christina M Feeley; Paul B Shyn; Kemal Tuncali; Stuart G Silverman Journal: J Vasc Interv Radiol Date: 2011-03-02 Impact factor: 3.464
Authors: S Mahner; S Schirrmacher; W Brenner; L Jenicke; C R Habermann; N Avril; J Dose-Schwarz Journal: Ann Oncol Date: 2008-03-19 Impact factor: 32.976
Authors: Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert Journal: N Engl J Med Date: 2003-06-19 Impact factor: 91.245
Authors: Elena Piperkova; Barbara Raphael; Mustafa E Altinyay; Ivan Castellon; Richard Libes; Nick Sandella; Sherif Heiba; Hussein Abdel-Dayem Journal: Clin Nucl Med Date: 2007-06 Impact factor: 7.794
Authors: Francois H Cornelis; Jeremy C Durack; Neeta Pandit-Taskar; Gary A Ulaner; Jason S Lewis; Michael J Morris; Stephen B Solomon Journal: J Nucl Med Date: 2017-08-17 Impact factor: 10.057
Authors: Francois H Cornelis; Jeremy C Durack; Michael J Morris; Howard I Scher; Stephen B Solomon Journal: Clin Nucl Med Date: 2017-12 Impact factor: 7.794
Authors: Michael C Burke; Ankur Garg; Jonathan M Youngner; Swati D Deshmukh; Imran M Omar Journal: Skeletal Radiol Date: 2018-10-20 Impact factor: 2.199